Timber Pharmaceuticals
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7 Giralda Farms, Madison, New Jersey, 07...Phone Number
(908) 636-7160Website
www.timberpharma.comRevenue
<$5 MillionStock Symbol
TMBRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Timber Pharmaceuticals
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. Timber is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma.Explore more
Timber Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Timber Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Timber Pharmaceuticals has new funding data
Check out if Timber Pharmaceuticals is spiking on competitors!
Timber Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Timber Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Timber Pharmaceuticals launches new products
Check if Timber Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Timber Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Timber Pharmaceuticals
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Timber Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Timber Pharmaceuticals
Compare insights from companies similar to Timber Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Timber Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Timber Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Timber Pharmaceuticals.
Timber Pharmaceuticals financials insights
Gather financial insights about Timber Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$500K
2015
Unspecified
$7.9M
Stock Offering
$12M
Timber Pharmaceuticals Tech Stack
A closer look at the technologies used by Timber Pharmaceuticals
Most Recent Scoops
Pain Point
Pain Point, Bankruptcy
Mergers & Acquisitions (M&A)
Mergers & Acquisitions (M&A)
Executive Move
Board of Directors
Executive Move
Board of Directors
Timber Pharmaceuticals News & Media
NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to immediately suspend trading in the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American. On November 21, 2023, the NYSE American announced that it was commencing proceedings to delist the Company. The Company had the right to request a review of this determination by the Listings QualificationsNYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003(c)(iii) of the NYSE American Company Guide in light of the CompaSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Timber Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - August 21, 2023) - Rigrodsky Law, P.A. is investigating Timber Pharmaceuticals, Inc. ("Timber") (NYSE: TMBR) regarding possible breaches of fiduciary duties and other violations of law related to Timber's agreement to be acquired by LEO Pharma A/S.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-timber-pharmaceuticals-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Timber Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety prof... Read More
